Table 2.
Logistic regression analysis showing factors independently associated with DAS-remission (DAS < 1.6) at 6 and 12 months of follow-up in a cohort of ERA patients treated according to the T2T strategy.
| DAS-remission (6 months FU) | DAS-remission (12 months FU) | |||
|---|---|---|---|---|
| Variables | Univariate analysis* OR (95%CI) | Logistic regression model OR (95%CI) | Univariate analysis* OR (95%CI) | Logistic regression model OR (95%CI) |
| Age, years | 0.97 (0.935–0.997) | 0.97 (0.95–0.99) | 0.98 (0.96–1.01) | 0.99 (0.96–1.01) |
| Sex (female) | 0.65 (0.30–1.41) | – | 0.55 (0.26–1.20) | – |
| VERA | 2.22 (1.08–4.55) | 2.75 (1.26–5.98) | 2.10 (1.03–4.28) | 2.05 (1.00–4.23) |
| Current Smokers, n. (%) | 0.72 (0.33–1.58) | – | 0.68 (0.32–1.44) | – |
| BMI ≥ 25 Kg/m2 | 0.65 (0.34–1.24) | – | 0.75 (0.38–1.49) | – |
| AB positivity, n. (%) | 1.23 (0.58–2.71) | – | 1.27 (0.60–2.66) | – |
| DAS > 3.7 (active disease at baseline) | 0.33 (0.15–0.76) | 0.37 (0.16–0.88) | 0.65 (0.32–1.35) | – |
| bDMARDs at 3 months FU | 0.51 (0.13–2.05) | – | 1.78 (0.49–6.42) | – |
| bDMARDs at 6 months FU | – | 1.14 (0.39–3.35) | – | |
| Chemerin ≥ 95.7 ng/ml | 0.47 (0.23–0.95) | 0.66 (0.31–1.43) | 0.48 (0.24–0.94) | 0.49 (0.25–0.97) |
| PEDF ≥ 13.3 μg/ml | 0.84 (0.42–1.67) | – | 1.03 (0.53–2.02) | – |
VERA, Very Early Rheumatoid Arthritis patients; BMI, Body Mass Index; AB, Autoantibodies; DAS, Disease Activity Score; bDMARDs, biological Disease Modifying Anti-Rheumatic Drugs; FU, follow-up; PEDF, Pigment Epithelium Derived Factor; OR, Odds Ratio; CI, Confidential Interval; FU, Follow-up.
*
Mann–Whitney U-test or χ2 test. Bold, p-value < 0.05.